Skip to main
FDMT

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics has demonstrated promising developments in its gene therapy candidate portfolio, particularly within the ophthalmology segment, where recent data from phase IIb trials indicate significant efficacy, with reductions of 94% and 92% in key measures through years one and one and a half, respectively. The company's strategic focus on one-time functional cures that offer safe, effective outcomes and lower system costs enhances its market position, alongside an improved benefit/risk profile for its lead candidates addressing wet AMD and diabetic macular edema. Additionally, 4D's strengthened cash position and collaboration with Otuska have increased the probability of success for advancing to phase III trials, underpinning a favorable outlook for investors.

Bears say

The financial outlook for 4D Molecular Therapeutics Inc is marked by significant uncertainties stemming from the potential underperformance of early trial results in later stages, which could lead to downward revisions in projected financial metrics. Additionally, the company faces challenges related to manufacturing capacity, which could materially constrain revenue forecasts and limit operational scalability. Coupled with the inherent risks associated with being a non-revenue generating entity, the stock's volatility could result in substantial swings that further complicate future financial projections.

FDMT has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Strong Buy based on their latest research and market trends.

According to 7 analysts, FDMT has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.